Urothelial carcinoma of the bladder (UC) has a poor prognosis, partly because of chemotherapy resistance. Molecular classifications have shown their interest and can help to offer personalized treatment.
Robot-assisted radical cystectomy (RARC) remains one of the most complex urological procedures. Due to regionalization of bladder cancer care, there is likely an imbalance in experience among urologists performing RARC.
Given the high recurrence and progression rates and the absence of reliable markers for early detection and prognosis prediction of patients with urothelial bladder cancer (BCa), the exploration of new biomarkers with high specificity is imperative.
The landscape of the health system was vastly impacted by the COVID-19 pandemic, spilling over to impact medical education. As social distancing guidelines required medical students and residents to be removed from clinical spaces, it was necessary that we reimagine how we deliver effective learning outside of the clinic. This was both crucial and opportune […]
Background Abiraterone and enzalutamide may increase the risk of cardiovascular events in patients with castration-resistant prostate cancer (CRPC). Methods A comprehensive literature search was performed using a combination of keywords related to “abiraterone,” “enzalutamide,” “prostate cancer,” and “adverse events.” Phase II–IV randomized controlled trials (RCTs) on abiraterone
Treatments for prostate cancer have rapidly evolved over the past nearly 10 years. Prior to this, the only approved life-prolonging agent for advanced prostate cancer was docetaxel. However, that all changed with the approval of abiraterone and enzalutamide. Both drugs showed profound benefits for men with metastatic castration-resistant prostate cancer (mCRPC). For these men, survival […]
It has now been approximately a year and a half since the United States Food and Drug Administration (FDA) granted accelerated approval to erdafitinib for patients with locally advanced or metastatic urothelial carcinoma, with susceptible fibroblast growth factor receptor 3 (FGFR3) or FGFR2 genetic alterations after progression during or following platinum chemotherapy.1 The label is inclusive […]
To start off Bladder Health month, I thought a discussion about urinary incontinence, a bladder concern of many women, especially those who have undergone pregnancy, would be appropriate. Pregnancy and childbirth are known risk factors for urinary incontinence (unintentional and involuntary loss of urine). But despite the fact that more than one-third of women experience […]
Management of urolithiasis in patients with chronic kidney disease. To ascertain the best method surgical or noninvasive. This was a single-institute study. A total of 50 patients of CKD with urolithiasis were enrolled in this comparative study.
Ureteric stone disease is increasing, especially in developed countries, and present in different ages with various patterns; it has many treatment modalities and outcomes. Ureteric stones are usually small and symptomatic but maybe large, asymptomatic associates with totally distracted kidneys.
